Introduction {#sec1}
============

Alpha-type platelet-derived growth factor receptor (PDGFRα) is a cell surface tyrosine kinase receptor for members of the platelet-derived growth factor family, which is encoded by the gene *PDGFRA*. Platelet-derived growth factor receptors (PDGFRs) are a family of catalytic receptors that play important roles in the regulation of several biological processes including embryonic development \[[@bib1]\], angiogenesis \[[@bib1],[@bib2]\], and cell proliferation and migration \[[@bib1],[@bib3]\]. PDGFRs contribute to the pathophysiology of a broad range of human diseases, including cancers. For example, PDGFRα was found to be expressed more frequently by tumor-associated stromal cells in lung cancer \[[@bib4]\]; overexpression of PDGFRα is associated with tumor progression in breast cancer \[[@bib5]\]; significant correlation was identified between PDGFRα expression and lymph node metastasis in colon cancer \[[@bib6]\]. Particularly, PDGFR signaling has been proposed to play a key role in malignant brain tumor of glial origin, such as glioma \[[@bib1]\]. Glioma is the most common primary tumors in the central nervous system. Glioma can be categorized based on pathological evaluation of the tumor. According to the World Health Organization (WHO) grading system, gliomas are classified into four grades (I, II, III, and IV) with the best prognosis in grade I and the most malignancy in grade IV. WHO grade I and II tumors are termed low-grade glioma. The term high-grade glioma refers to tumors that are classified as WHO grade III, such as anaplastic astrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, and anaplastic ependymoma, and WHO grade IV, such as glioblastoma. Amplification of PDGFRα has been observed in both low-grade \[[@bib7]\] and high-grade \[[@bib8],[@bib9]\] gliomas. In addition, overexpression of the gene *PDGFRA* in glioma at the time of the first diagnosis was found to be associated with poor overall survival \[[@bib10]\]. Inhibition of PDGFRs has been shown to slow down glioma cell growth in experimental models \[[@bib1]\]. Therefore, inhibition of PDGFR signaling has become one of the targeted therapeutic strategies for glioma \[[@bib11]\].

Although the pathological function of PDGFRs in gliomas remains controversial, coexpression module based on the gene *PDGFRA* has been developed to enable the molecular classification of glioma for clinical diagnosis \[[@bib12]\]. It is also reasonable to hypothesize that the genes directly or indirectly influenced by PDGFRα might be useful for prognostic purpose in glioma. Here, we utilized high-throughput gene expression data to identify the genes potentially influenced by PDGFRα in glioma. We compared the genome-wide gene expression pattern between PDGFRα^+^ and PDGFRα^−^ cells from human oligodendrocyte progenitor \[[@bib13]\]. The genes deregulated in PDGFRα^+^ cells were considered as PDGFRα influenced genes. Gene ontology analysis indicates that the PDGFRα-influenced genes are strongly associated with cancer-related pathways. We subsequently developed a prognostic gene signature derived from the PDGFRα influenced genes. This gene signature is able to predict clinical outcome in two independent glioma cohorts. This signature is also independent of traditional prognostic factors in glioma. Our study suggests that the PDGFRα-influenced genes potentially serve as biomarkers and therapeutic targets in clinical and pharmacological contexts, respectively.

Materials and Methods {#sec2}
=====================

Gene Expression Data Sets {#sec2.1}
-------------------------

We obtained the gene expression data for both PDGFRα^+^ and PDGFRα^−^ oligodendrocyte progenitor cells from the Gene Expression Omnibus (GEO) database \[[@bib14]\] (GEO accession: [GSE29368](ncbi-geo:GSE29368){#intref0010}), which was based on the Affymetrix Human Genome U133 Plus 2.0 Array \[[@bib13]\]. In the original study, the PDGFRα^+^ cells were defined based on expression of the PDGFRα epitope CD140a, which were sorted from the fetal human forebrain using FACS \[[@bib13]\]. The gene expression data from University Hospital of Coimbra (UHC), Portugal (GEO accession: [GSE43289](ncbi-geo:GSE43289){#intref0015}) \[[@bib15]\] and Henry Ford Hospital (HFH), USA (GEO accession: [GSE4290](ncbi-geo:GSE4290){#intref0020}) \[[@bib16]\] were used to identify the glioma related genes, in which the gene expression level was significantly correlated with WHO glioma grade. Both the UHC and HFH data sets were based on the Affymetrix Human Genome U133 Plus 2.0 Array. The gene expression data from Shanghai Changzheng Hospital (SCH), China (GEO accession: [GSE19728](ncbi-geo:GSE19728){#intref0025}) \[[@bib17]\], was used to validate the relationship between glioma grade and our PDGFRα-influenced gene signature (PIGS), which was also based on the Affymetrix Human Genome U133 Plus 2.0 Array. To validate the prognostic power of the gene signature, we collected two independent cohorts with available clinical outcome information: the EORTC (European Organisation for Research and Treatment of Cancer) cohort (GEO accession: [GSE43107](ncbi-geo:GSE43107){#intref0030}) \[[@bib18]\] and the UCLA (University of California at Los Angeles) cohort (GEO accession: [GSE4412](ncbi-geo:GSE4412){#intref0035}) \[[@bib19]\], which were based on Affymetrix Human Exon 1.0 ST Array and Affymetrix Human Genome U133A/B Array, respectively. [Figure 1](#fig1){ref-type="fig"} indicates the working scheme of how all these transcriptomic data sets were implicated in this study.Figure 1**The working scheme of the study.** We first compared the transcriptomic pattern between PDGFRα^+^ and PDGFRα^−^ cells from human oligodendrocyte progenitor, which yielded a list of PDGFRα-influenced genes. Next, the UHC and HFH cohorts were analyzed to infer the glioma-related genes, which were either positively or negatively correlated with glioma grade. We developed a gene signature based on the intersection between the upregulated genes in high-grade glioma and the overexpressed genes in PDGFRα^+^ cells and the intersection between the downregulated genes in high-grade glioma and the underexpressed genes in PDGFRα^+^ cells. We validated the power of this gene signature in grade prediction in the SCH cohort. We further validated the predictive power of the gene signature in differentiating glioma patients with distinct survivals in the EORTC and UCLA cohorts.Figure 1

Microarray Data Processing {#sec2.2}
--------------------------

We applied the robust multiarray average (RMA) function in the "affy" package of bioconductor \[[@bib20]\] to summarize the expression level of each probeset for the data sets generated by Affymetrix Human Genome U133 Plus 2.0 Array and Affymetrix Human Genome U133A/B Array. For the data set based on Affymetrix Human Exon 1.0 ST Array, the gene expression values were summarized using the Affymetrix Power Tools Version 1.15.0. The function "mas5calls" in the "affy" package \[[@bib21]\] was used to compute probeset present/absent call for the progenitor cell, UHC, and HFH data sets. For the progenitor cell data set, only the probesets that were present in all replicates of at least one group were used for further analysis. For the UHC and HFH data sets, only the probesets that were present in at least two-thirds of the samples were retained. We limited our analysis to the probesets with unique annotations. The genes on chromosomes X and Y were removed. For the SCH, EORTC, and UCLA data sets, we used the geometric mean of expression values of all probesets mapping to a gene if the gene was encoded by multiple probesets. Significance analysis of microarrays \[[@bib22]\], implemented in the samr library of the R Statistical Package, was used to compare log~2~-transformed gene expression levels between PDGFRα^+^ and PDGFRα^−^ progenitor cells. False discovery rate (FDR) was controlled using the q-value method \[[@bib23],[@bib24]\]. Transcripts with FDR \< 5% and FC \> 2 were deemed differentially expressed.

Risk Score {#sec2.3}
----------

We used a published scoring system to compute the risk score for each patient \[[@bib25], [@bib26], [@bib27]\]. The risk score is a linear combination of gene expression values. The formula is shown below:$$S = \sum\limits_{i = 1}^{n}{{W_{i}\left( {e_{i} - \mu_{i}} \right)}/\tau_{i}}$$Here, *S* is the risk score of the patient; *n* is the number of genes in PIGS; *W*~*i*~ denotes the weight of gene *i* (as shown in [Table 1](#tbl1){ref-type="table"}); *e*~*i*~ denotes the expression level of gene *i*; and *μ*~*i*~ and *τ*~*i*~ are the mean and standard deviation of the expression values for gene *i* across all subjects, respectively. A higher risk score implies a poorer clinical outcome.Table 1The 28 genes of PIGS.Table 1Gene symbolGene titleWeight*ANXA1*Annexin A11*ANXA2*Annexin A21*CD63*CD63 molecule1*CHI3L1*Chitinase 3-like 1 (cartilage glycoprotein-39)1*DTX3L*Deltex 3-like (*Drosophila*)1*FNDC3B*Fibronectin type III domain containing 3B1*HRH1*Histamine receptor H11*ITGA7*Integrin, alpha 71*MRC2*Mannose receptor, C type 21*PPIC*Peptidylprolyl isomerase C (cyclophilin C)1*ATP6V1G2*ATPase, H+ transporting, lysosomal 13 kDa, V1 subunit G2−1*ATRNL1*Attractin like 1−1*C20orf194*Chromosome 20 open reading frame 194−1*CAMTA1*Calmodulin-binding transcription activator 1−1*CAND1*Cullin-associated and neddylation-dissociated 1−1*CCDC90A*Coiled-coil domain containing 90A−1*CLASP2*Cytoplasmic linker associated protein 2−1*CPEB3*Cytoplasmic polyadenylation element binding protein 3−1*ERBB4*v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian)−1*GTF2H5*General transcription factor IIH, polypeptide 5−1*NTN4*Netrin 4−1*PLEKHM3*Pleckstrin homology domain containing, family M, member 3−1*POU6F1*POU class 6 homeobox 1−1*PTPN4*Protein tyrosine phosphatase, nonreceptor type 4 (megakaryocyte)−1*RALGPS1*Ral GEF with PH domain and SH3 binding motif 1−1*SGIP1*SH3-domain GRB2-like (endophilin) interacting protein 1−1*TMEM57*Transmembrane protein 57−1*ZNF33A*Zinc finger protein 33A−1

Results {#sec3}
=======

Genes Influenced by PDGFRα {#sec3.1}
--------------------------

We compared the gene expression pattern between PDGFRα^+^ and PDGFRα^−^ cells from human oligodendrocyte progenitor. One PDGFRα^+^ cells microarray data set containing gene expression information for both PDGFRα^+^ and PDGFRα^−^- cells was collected from the GEO database \[[@bib14]\] (GEO accession: [GSE29368](ncbi-geo:GSE29368){#intref0040}) \[[@bib13]\], which was based on the Affymetrix Human Genome U133 Plus 2.0 Array. At the specified significance level of FDR \< 5% and fold change (FC) \> 2 (see [Materials and Methods](#sec2){ref-type="sec"} for details), 1445 probesets encoding 1076 genes were found to be overexpressed in PDGFRα^+^ cells ([Supplementary Table S1](#appsec1){ref-type="sec"} and [Figure S1](#appsec1){ref-type="sec"}), while 741 probesets encoding 541 genes were underexpressed in PDGFRα^+^ cells ([Supplementary Table S2](#appsec1){ref-type="sec"} and [Figure S1](#appsec1){ref-type="sec"}). We considered these deregulated genes as PDGFRα-influenced genes. We next searched the enriched Kyoto Encyclopedia of Genes and Genomes (KEGG) \[[@bib28]\] pathways among the PDGFRα-influenced genes. We found that the PDGFRα-influenced genes are significantly associated with several cancer-related KEGG terms, such as "colorectal cancer," "pathways in cancer," "melanoma," "prostate cancer," and "glioma" ([Figure 2](#fig2){ref-type="fig"}). These findings suggest that the PDGFRα-influenced genes are involved in human cancer pathogenesis.Figure 2**The top 20 KEGG pathways associated with the PDGFRα-influenced genes.** The *P*-values were calculated by Fisher\'s exact test. The vertical dash line denotes the significance level of *α* = 0.05.Figure 2

To determine how deep the PDGFRα-influenced genes are involved in glioma, we explored the genes that are associated with the severity of glioma. We obtained two gene expression data sets of glioma patients from the GEO database: the UHC cohort (GEO accession: [GSE43289](ncbi-geo:GSE43289){#intref0045}) \[[@bib15]\] and the HFH cohort (GEO accession: [GSE4290](ncbi-geo:GSE4290){#intref0050}) \[[@bib16]\]. Both data sets were based on the Affymetrix Human Genome U133 Plus 2.0 Array. There were 40 subjects in the UHC cohort, which included 3 grade I, 3 grade II, 6 grade III, and 28 grade IV patients. For the HFH cohort, there were in total 176 samples including 23 nontumor, 45 grade II, 31 grade III, and 77 grade IV subjects. Spearman\'s rank correlation test was used to identify the glioma related genes, in which the gene expression level was significantly correlated with glioma grade. Only the genes differentially expressed with glioma grade (Spearman\'s rank correlation test: adjusted *P* \< 0.005 after Benjamini--Hochberg correction) in the both cohorts were retained for further analysis. In total, we found that 81 probesets encoding 67 genes were upregulated in high-grade glioma ([Figure 3](#fig3){ref-type="fig"}A and [Supplementary Table S3](#appsec1){ref-type="sec"}) while 340 probesets encoding 275 genes were downregulated in high-grade glioma ([Figure 3](#fig3){ref-type="fig"}A and [Supplementary Table S4](#appsec1){ref-type="sec"}). Interestingly, the genes that were upregulated in high-grade glioma were more likely to be overexpressed in PDGFRα^+^ cells, compared with the downregulated genes ([Figure 3](#fig3){ref-type="fig"}B). Among the upregulated genes in high-grade glioma, 10 genes were found to overlap with the overexpressed genes in PDGFRα^+^ cells, which is statistically significant (cumulative hypergeometric test: *P* = 5.0 × 10^−3^). For the downregulated genes in high-grade glioma, 18 genes significantly overlapped with the underexpressed genes in PDGFRα^+^ cells (cumulative hypergeometric test: *P* = 2.7 × 10^−2^). All these results suggest that the PDGFRα-influenced genes are significantly enriched among the glioma associated gene set.Figure 3**Relationship between glioma grade and the PDGFRα-influenced genes.** (A) Glioma-related genes. Each dot stands for a gene. Spearman\'s rank correlation test was used to calculate the correlation between glioma grade and gene expression for the both UHC and HFH cohorts. The correlation coefficient of the UHC cohort (*ρ*~UHC~) is significantly correlated with the correlation coefficient of the HFH cohort (*ρ*~HFH~) (Pearson correlation test: *r* = 0.71 and *P* \< 10^−10^). Only the genes differentially expressed with glioma grade in the both cohorts were considered as glioma-related genes. The dark gray filled dots denote the genes upregulated in high-grade glioma, while the white filled dots represent the genes downregulated in high-grade glioma. The red line shows lowess-smoothed data. (B) Comparison between the genes upregulated and downregulated in high-grade glioma. Y-axis denotes the log~2~-transformed fold change (FC) in gene expression between PDGFRα^+^ and PDGFRα^−^ cells. Log~2~FC is significantly higher for the genes upregulated in high-grade glioma (*t*-test: *P* = 2.8 × 10^−7^), which suggests that the genes upregulated in high-grade glioma are more likely to be overexpressed in PDGFRα^+^ cells. (C) Positive correlation between glioma grade and PIGS-based risk score in the SCH cohort. Each dot stands for a patient from the SCH cohort. The horizontal line indicates the mean of each category. Spearman\'s rank correlation test: *ρ* = 0.70 and *P* = 1.7 × 10^−3^.Figure 3

PDGFRα-influenced Gene Signature {#sec3.2}
--------------------------------

Above, we identified 10 genes within the intersection between the upregulated genes in high-grade glioma and the overexpressed genes in PDGFRα^+^ cells. In addition, 18 downregulated genes in high-grade glioma were found to overlap with the underexpressed genes in PDGFRα^+^ cells. We designated all these 28 genes as PIGS ([Table 1](#tbl1){ref-type="table"} and [Supplementary Figures S2 and S3](#appsec1){ref-type="sec"}). Based on the PIGS, we constructed a scoring system to assign each subject a risk score, representing a linear combination of the PIGS expression values weighted by the direction of differential expression: 1 for the upregulated and −1 for the downregulated genes in PDGFRα^+^ cells (see [Materials and Methods](#sec2){ref-type="sec"} for details). A higher risk score suggests a poorer clinical outcome.

We first tested whether the PIGS based risk score was able to predict glioma grade. For this purpose, we obtained an independent gene expression data sets, the SCH cohort, from the GEO database including 17 glioma patients (GEO accession: [GSE19728](ncbi-geo:GSE19728){#intref0055}) \[[@bib17]\]. As we expected, there was a significant positive correlation (Spearman\'s rank correlation test: *P* = 1.7 × 10^−3^) between glioma grade and PIGS-based risk score ([Figure 3](#fig3){ref-type="fig"}C).

PIGS Predicts Survival in Glioma {#sec3.3}
--------------------------------

We next tested whether the PIGS-based risk score can be used to predict survival in glioma. From the GEO database, we downloaded two independent gene expression data sets: the EORTC cohort including 95 high-grade glioma patients (GEO accession: [GSE43107](ncbi-geo:GSE43107){#intref0060}) \[[@bib18]\] and the UCLA cohort composed of 85 high-grade glioma patients (GEO accession: [GSE4412](ncbi-geo:GSE4412){#intref0065}) \[[@bib19]\]. These data sets were chosen based on two criteria: (i) the large number of samples (sample size ≥ 80) and (ii) the availability of clinical outcome data. We defined PIGS positive (PIGS^+^) patients as those having a risk score \> 0, while the other patients were assigned as PIGS negative (PIGS^−^), as the median of risk score was approximately equal to zero in each validation cohort ([Supplementary Figure S4](#appsec1){ref-type="sec"}). Univariate Cox proportional hazard regression of survival indicates that the PIGS^+^ patients have a 2.91- and 2.46-increased risk of death in the EORTC and UCLA cohorts, respectively ([Table 2](#tbl2){ref-type="table"}). Kaplan--Meier survival curves demonstrate a significant difference in survival between the PIGS^+^ and PIGS^−^ glioma patients in the two validation cohorts (log-rank test: *P* = 2.2 × 10^−6^ for the EORTC cohort and *P* = 8.1 × 10^−4^ for the UCLA cohort) ([Figure 4](#fig4){ref-type="fig"}A).Table 2Univariate Cox proportional hazards regression of survival by PIGS status.Table 2Cohort*N*HR95% CI of HR*P*-valueEORTC952.91(1.84, 4.61)5.5 × 10^−6^UCLA852.46(1.43, 4.23)1.2 × 10^−3^[^1]Figure 4**PIGS predicts survival in glioma in the validation cohorts.** (A) Kaplan--Meier curves for the glioma patients from the EORTC and UCLA cohorts. The black curves are for the PIGS^+^ patients, while the gray curves are for the PIGS^−^ patients. *P*-values were calculated by log-rank test. (B) Superior prognostic power of PIGS compared with random gene signature. The dark gray area shows the distribution of Z for the 1000 resampled gene signatures picked up from human genome with identical size as PIGS. The dark gray area shows the distribution of Z for the 1000 resampled gene signatures selected from the glioma-related genes. The black triangle stands for the Z-value of PIGS. Right-tailed *P*-values of the sampling distributions were calculated.Figure 4

Nonrandom Prognostic Power of PIGS {#sec3.4}
----------------------------------

Venet et al. suggested that most published prognostic gene signatures were not significantly better than random gene sets of identical size that were randomly picked up from human genome \[[@bib29]\]. Here, resampling tests were used to address this issue. We generated 1000 random gene signatures by randomly selecting 28 genes from human genome (the same size as PIGS). For each random gene signature, we calculated the risk score for each glioma patient. Univariate Cox proportional hazard regression of survival was used to evaluate the association between the random gene signature and clinical outcome. For each round of randomization (i.e., each randomly generated 28-gene list), we calculated the Wald statistic (*Z*), the ratio of Cox regression coefficient to its standard error, which stands for the prognostic power of the 28 random genes. Our alternative hypothesis was that the *Z* of PIGS should be more positive than expected by chance if the prognostic power of PIGS was significantly better than the random gene signatures. [Figure 4](#fig4){ref-type="fig"}B demonstrates that the *Z* of PIGS is significantly larger than that of the random gene sets in the two validation cohorts (right-tailed: *P* = 0.003 for the EORTC cohort and *P* = 0.015 for the UCLA cohort).

PIGS is Better than the Random Gene Signatures Selected from Glioma-related Genes {#sec3.5}
---------------------------------------------------------------------------------

Here, we address why we focused on the PDGFRα-influenced genes to develop prognostic signature. To answer this question, we compared the performance of PIGS against the gene set associated with glioma by a second resampling test. We limited the resampling pool to the genes that were differentially expressed with glioma grade ([Supplementary Tables S3](#appsec1){ref-type="sec"} and [S4](#appsec1){ref-type="sec"}) and defined these genes as glioma related. We then randomly selected 28 genes from the glioma-related gene pool and tested the predictive power of the random gene set. The performance of the random gene signature was also quantified by the *Z*-value computed by univariate Cox proportional hazard regression of survival. We found that the prognostic power of PIGS is significantly better than that of 1000 random glioma-related gene signatures in the both validation cohorts (right-tailed: *P* = 0.002 for the EORTC cohort and *P* = 0.047 for the UCLA cohort) ([Figure 4](#fig4){ref-type="fig"}B). These results suggest that the prognostic signature derived from the PDGFRα-influenced genes is superior to the gene sets filtered out by unbiased approaches.

PIGS is Independent of Standard Prognostic Covariates {#sec3.6}
-----------------------------------------------------

To confirm the role of PIGS as an independent prognostic factor, we investigated the performance of PIGS in comparison with the traditional prognostic variables in glioma. Because of the limited clinical and pathological information, we did not consider the UCLA cohort. Only the EORTC cohort was investigated by multivariate model.

Firstly, we only considered the prognostic variables including age, gender, type of surgery (biopsy, partial, or total resection), Eastern Cooperative Oncology Group (ECOG) performance score \[[@bib30]\], loss of heterozygosity (LOH) on chromosome 1p and 19q \[[@bib31]\], and histological status (anaplastic oligoastrocytoma or anaplastic oligodendroglioma). There were 89 patients without missing data. Multivariate Cox proportional hazards regression of survival indicates that PIGS is the most significant covariate compared with the other clinical and pathological factors ([Table 3](#tbl3){ref-type="table"}).Table 3Multivariate Cox proportional hazards regression conducted on 89 patients from the EORTC cohort.Table 3CovariateHR95% CI of HR*P*-valuePIGS, + vs. −3.46(2.04, 5.84)3.7 × 10^−6^Age (per year)1.03(1.00, 1.06)6.7 × 10^−2^Gender male vs. female0.94(0.55, 1.61)8.4 × 10^−1^Type of surgery (biopsy, partial, or total resection)0.65(0.43, 0.97)3.7 × 10^−2^ECOG performance score (0, 1, or 2)1.51(1.08, 2.10)1.7 × 10^−2^1p/19q LOH, + vs. −0.87(0.43, 1.75)6.9 × 10^−1^Histology AOA vs. AOD1.70(0.95, 3.04)7.4 × 10^−2^[^2]

Secondly, we took more molecular factors into account, including epidermal growth factor receptor (*EGFR*) amplification \[[@bib32]\], isocitrate dehydrogenase 1 (*IDH1*) mutation \[[@bib32]\], and O-6-methylguanine-DNA methyltransferase (*MGMT*) promoter methylation \[[@bib33]\]. Because of missing observations, only 53 patients were included in this round. Multivariate Cox proportional hazards regression reveals that PIGS is still the most significant covariate in the new multivariate model ([Table 4](#tbl4){ref-type="table"}).Table 4Multivariate Cox proportional hazards regression conducted on 53 patients from the EORTC cohort.Table 4CovariateHR95% CI of HR*P*-valuePIGS, + vs. −6.10(2.48, 15.00)8.2 × 10^−5^Age (per year)1.05(1.00, 1.10)4.5 × 10^−2^Gender male vs. female1.75(0.76, 4.05)1.9 × 10^−1^Type of surgery (biopsy, partial, or total resection)0.31(0.16, 0.58)3.2 × 10^−4^ECOG performance status (0, 1, or 2)1.01(0.59, 1.72)9.7 × 10^−1^1p/19q LOH, + vs. −0.57(0.15, 2.10)3.9 × 10^−1^*EGFR* amplification, + vs. −1.37(0.58, 3.25)4.8 × 10^−1^*IDH1* mutation, + vs. −0.40(0.16, 1.01)5.2 × 10^−2^*MGMT* methylation, + vs. −3.53(1.19, 10.53)2.4 × 10^−2^Histology AOA vs. AOD1.18(0.49, 2.86)7.1 × 10^−1^[^3]

From [Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}, we can notice that patient age, type of surgery, ECOG performance score, and *MGMT* methylation status are also significant variables in multivariate model. Therefore, we further stratified the patients in the EORTC cohort according to respective significant factors and redid Cox proportional hazards regression. For patients with age ≤ 45, 45 \< age ≤ 55, and age ≥ 55, PIGS^+^ patients had 2.78-fold (*P* = 1.2 × 10^−2^), 3.04-fold (*P* = 7.7 × 10^−3^), and 3.09-fold (*P* = 1.4 × 10^−2^) increased risk for death, respectively. For patients with biopsy, partial resection, and total resection, PIGS^+^ patients had 9.15-fold (*P* = 4.2 × 10^−2^), 3.18-fold (*P* = 3.9 × 10^−4^), and 2.73-fold (*P* = 1.7 × 10^−2^) increased risk for death, respectively. For patients with ECOG performance score 0, 1, and 2, PIGS^+^ patients had 2.24-fold (*P* = 4.2 × 10^−2^), 3.99-fold (*P* = 2.8 × 10^−4^), and 4.69-fold (*P* = 1.7 × 10^−2^) increased risk for death, respectively. For patients with methylated *MGMT* promoter, PIGS^+^ patients had 3.52-fold (*P* = 3.2 × 10^−4^) increased risk for death. Kaplan--Meier survival curves also demonstrate significantly reduced survival for PIGS^+^ patients in each subset grouped by age, type of surgery, ECOG performance score, and *MGMT* methylation status ([Figure 5](#fig5){ref-type="fig"}). Taken together, these results suggest that PIGS is an independent prognostic variable and enhances the identification of glioma patients at greater risk for death.Figure 5**Kaplan--Meier curves for glioma patients grouped by clinical and pathological factors.** (A) Patients were stratified by age. (B) Patients were stratified by surgery type. (C) Patients were stratified by ECOG performance score. (D) Patients were stratified by MGMT promoter methylation status. The black curves are for the PIGS^+^ patients, while the gray curves are for the PIGS^−^ patients. *P*-values were calculated by log-rank test.Figure 5

Discussion {#sec4}
==========

PDGFRα plays a role in organ development, wound healing, and tumor progression. Mutations in the gene PDGFRA have been associated with a variety of human cancers \[[@bib34], [@bib35], [@bib36]\]. In addition, elevated PDGFRα expression was found in several human tumors \[[@bib4], [@bib5], [@bib6],[@bib35]\], particularly in glioma \[[@bib1],[@bib7],[@bib10]\]. In this study, we investigated the prognostic power of PDGFRα-influenced genes in glioma. By comparing the genome-wide gene expression pattern between PDGFRα^+^ and PDGFRα^−^ cells, we defined the genes potentially influenced by PDGFRα. These genes are strongly associated with cancer-related KEGG pathways. We subsequently developed a prognostic gene signature, PIGS, which was composed of 28 PDGFRα-influenced protein-coding genes. We indicate that PIGS-based risk score can be used to predict glioma grade. In addition, PIGS is able to predict clinical outcome in two independent glioma cohorts.

Multivariate Cox regression indicates that PIGS outperforms the traditional prognostic factors of glioma. Besides PIGS status, we considered nine clinical and pathological variables in the multivariate model, including age, gender, surgery type, ECOG performance score, 1p/19q LOH status, EGFR amplification status, IDH1 mutation status, MGMT promoter methylation status, and histological status. PIGS-based risk score is the most significant covariate compared with all the other factors. Even we stratified the data sets according to the other significant covariates, PIGS was still able to differentiate the patients with poor outcome from the long survival ones in each subgroup. These results confirm that PIGS is not dependent on specific values of the respective covariates. PIGS working cooperatively with traditional clinical and pathological factors may increase prognostic accuracy when identifying patients at higher risk of death in glioma.

A controversial computational study by Venet et al. suggested that the majority of published prognostic gene signatures of breast cancer were not significantly better than random gene sets of identical size that were randomly selected from human genome \[[@bib29]\]. To address this issue in our study, we conducted a resampling test by randomly selecting 28 genes (the same size as PIGS) from human transcriptome and calculated the prognostic power for the random gene signature. The resampling test indicates that PIGS is superior to the random gene sets selected from human genome. However, it should also be noted that, in the EORTC cohort, the *Z*-value is larger than two (2.3% percentile in normal distribution) for almost half of the random gene signatures ([Figure 4](#fig4){ref-type="fig"}B). Therefore, the performance of a prognostic signature for glioma should not only be measured by the nominal *P*-values generated by Cox regression or log-rank test as many randomly generated gene signatures could also classify subjects with a fairly significant nominal *P*-value. Therefore, we suggest that resampling test should be a standard procedure when generating prognostic biomarkers for specific human disease. Nominal *P*-values only address the statistical question as to whether the given gene set is related to disease, but not the question whether the gene set is more related to disease than random gene sets \[[@bib29]\]. Resampling test also demonstrates that the prognostic power of PIGS is even better than the random signatures selected from the gene pool that are differentially expressed in glioma. This result addressed the question why we only developed gene signature around PDGFRα instead of using unbiased screening.

Conclusions {#sec5}
===========

Despite the absence of clear elucidation of molecular mechanisms, this study suggests the vital role of PDGFRα in carcinogenesis. Furthermore, the PDGFRα-based gene signature provides a promising prognostic tool for glioma and validates PDGFRα as a novel and effective therapeutic target in human cancers.
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[^1]: *N*: patient number; HR: hazard ratio; CI: confidence interval.

[^2]: HR: hazard ratio; CI: confidence interval; AOA: anaplastic oligoastrocytoma; AOD: anaplastic oligodendroglioma.

[^3]: HR: hazard ratio; CI: confidence interval; AOA: anaplastic oligoastrocytoma; AOD: anaplastic oligodendroglioma.
